International AIDS Vaccine Initiative, New York, New York 10038-3901, USA.
AIDS. 2010 Oct;24 Suppl 4:S50-60. doi: 10.1097/01.aids.0000390707.58512.5e.
Since HIV-1 was identified, development of a preventive vaccine has been a major goal. Significant progress toward that goal has been made by 2010. In macaques, a vigorous T effector cell response has protected some animals from disease caused by simian immunodeficiency virus (SIV). Broadly, neutralizing human anti-HIV antibodies have been isolated and their structures, and targets are rapidly being elucidated. For the first time an AIDS vaccine has shown modest protective efficacy in a human clinical trial. To reach the final goal, there is a need for a coordinated global effort, including a range of approaches including novel high-throughput screening techniques, X-ray crystallography, and monoclonal antibody isolation, analysis of T cell responses and their impact on disease progression, human epidemiology, as well as targeted studies in nonhuman primates. African research teams as well as cohorts of healthy volunteers and HIV-infected individuals have contributed to HIV vaccine research and development in many important ways. It is essential that this work continue to speed the development and deployment of a vaccine suitable for African populations.
自 HIV-1 被发现以来，开发预防性疫苗一直是一个主要目标。到 2010 年，这一目标已经取得了重大进展。在猕猴中，强烈的 T 效应细胞反应保护了一些动物免受猴免疫缺陷病毒（SIV）引起的疾病的侵害。广泛地说，已经分离出中和人类抗 HIV 抗体，并且正在迅速阐明其结构和靶标。艾滋病疫苗首次在人体临床试验中显示出适度的保护效力。为了达到最终目标，需要协调全球努力，包括一系列方法，包括新型高通量筛选技术、X 射线晶体学和单克隆抗体分离、T 细胞反应及其对疾病进展的影响的分析、人类流行病学以及非人类灵长类动物的靶向研究。非洲研究团队以及健康志愿者和 HIV 感染者队列以许多重要方式为 HIV 疫苗研究和开发做出了贡献。至关重要的是，这项工作继续加快适合非洲人群的疫苗的开发和部署。
